Yanchik Connealy Pamela's Form 4 filing
Pyxis Oncology, Inc.PYXS · filed Sep 27, 2023
- Accession no.
- 0001209191-23-050685
- Filed
- Sep 27, 2023
- Trade date
- Sep 27, 2023
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $11.9K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Yanchik Connealy PamelaCIK 0001796310 | Officer (CFO and COO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 27, 2023 | Common Stock | PPurchaseAcquired | +6,426 | $1.85F1 | +$11,888.1 | 810,532 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents the weighted average purchase price of common stock purchased by the Reporting Person in open market transactions. The range of purchase prices on the transaction date was $1.78 to $1.87 per share. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each price.
Referenced by the price of 1 transaction in Table I.